JP2009541493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541493A5 JP2009541493A5 JP2009518522A JP2009518522A JP2009541493A5 JP 2009541493 A5 JP2009541493 A5 JP 2009541493A5 JP 2009518522 A JP2009518522 A JP 2009518522A JP 2009518522 A JP2009518522 A JP 2009518522A JP 2009541493 A5 JP2009541493 A5 JP 2009541493A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- branched
- linear
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 208000014674 injury Diseases 0.000 claims 9
- 230000008733 trauma Effects 0.000 claims 9
- 102000001972 Galanin receptor 3 Human genes 0.000 claims 8
- 108050009372 Galanin receptor 3 Proteins 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 239000002464 receptor antagonist Substances 0.000 claims 7
- 229940044551 receptor antagonist Drugs 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 6
- 230000005779 cell damage Effects 0.000 claims 6
- 208000037887 cell injury Diseases 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 150000002466 imines Chemical class 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 210000002569 neuron Anatomy 0.000 claims 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- -1 methylenedioxy group Chemical group 0.000 claims 4
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 239000002966 varnish Substances 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000008485 antagonism Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 210000001178 neural stem cell Anatomy 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000037920 primary disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000003808 Amyloid Neuropathies Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 102000019432 Galanin Human genes 0.000 claims 1
- 101800002068 Galanin Proteins 0.000 claims 1
- 208000009119 Giant Axonal Neuropathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 1
- 241000097929 Porphyria Species 0.000 claims 1
- 208000010642 Porphyrias Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 210000005155 neural progenitor cell Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 230000014511 neuron projection development Effects 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81668206P | 2006-06-26 | 2006-06-26 | |
| PCT/US2007/072166 WO2008002946A2 (en) | 2006-06-26 | 2007-06-26 | Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168863A Division JP2013227357A (ja) | 2006-06-26 | 2013-08-15 | ガラニン−３レセプターアンタゴニストの使用による神経突起伸長の調節方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009541493A JP2009541493A (ja) | 2009-11-26 |
| JP2009541493A5 true JP2009541493A5 (enExample) | 2010-07-22 |
Family
ID=38738789
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518522A Pending JP2009541493A (ja) | 2006-06-26 | 2007-06-26 | ガラニン−３レセプターアンタゴニストの使用による神経突起伸長の調節方法 |
| JP2013168863A Pending JP2013227357A (ja) | 2006-06-26 | 2013-08-15 | ガラニン−３レセプターアンタゴニストの使用による神経突起伸長の調節方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168863A Pending JP2013227357A (ja) | 2006-06-26 | 2013-08-15 | ガラニン−３レセプターアンタゴニストの使用による神経突起伸長の調節方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080039496A1 (enExample) |
| EP (1) | EP2032135A2 (enExample) |
| JP (2) | JP2009541493A (enExample) |
| CN (1) | CN101484159A (enExample) |
| AU (1) | AU2007265088B2 (enExample) |
| BR (1) | BRPI0712938A2 (enExample) |
| CA (1) | CA2655829A1 (enExample) |
| IL (1) | IL195903A0 (enExample) |
| MX (1) | MX2008016083A (enExample) |
| SG (1) | SG172735A1 (enExample) |
| WO (1) | WO2008002946A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7642281B2 (en) * | 2002-08-07 | 2010-01-05 | Helicon Therapeutics, Inc. | Indolone compounds useful to treat cognitive impairment |
| BRPI0916228A2 (pt) * | 2008-07-18 | 2015-11-03 | Dart Neuroscience Llc | métodos e sistemas para avaliação de agentes de memória |
| US20100028839A1 (en) * | 2008-07-18 | 2010-02-04 | Tully Timothy P | Methods and systems for evaluating memory agents |
| EP2680842A4 (en) * | 2011-03-02 | 2014-10-29 | Bionomics Ltd | METHOD FOR THE TREATMENT OF A DISEASE OR A SENSE OF THE CENTRAL NERVOUS SYSTEM |
| US8277842B1 (en) | 2012-01-20 | 2012-10-02 | Dart Neuroscience (Cayman) Ltd. | Enteric-coated HT-2157 compositions and methods of their use |
| PE20161476A1 (es) * | 2014-06-26 | 2017-01-07 | Hoffmann La Roche | Derivados de indolin-2-ona o pirrolo-piridin-2-ona |
| HUE050083T2 (hu) * | 2015-11-06 | 2020-11-30 | Hoffmann La Roche | Indolin-2-on származékok |
| JP6857653B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体 |
| EP3371174B1 (en) | 2015-11-06 | 2021-03-17 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives |
| JP6857651B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7081470B2 (en) * | 2001-01-31 | 2006-07-25 | H. Lundbeck A/S | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| US7220775B2 (en) * | 2002-08-07 | 2007-05-22 | H. Lundbeck A/S | Compound useful for the treatment of neuropathic pain |
-
2007
- 2007-06-26 MX MX2008016083A patent/MX2008016083A/es not_active Application Discontinuation
- 2007-06-26 CA CA002655829A patent/CA2655829A1/en not_active Abandoned
- 2007-06-26 BR BRPI0712938-6A patent/BRPI0712938A2/pt not_active IP Right Cessation
- 2007-06-26 EP EP07799059A patent/EP2032135A2/en not_active Withdrawn
- 2007-06-26 WO PCT/US2007/072166 patent/WO2008002946A2/en not_active Ceased
- 2007-06-26 AU AU2007265088A patent/AU2007265088B2/en not_active Ceased
- 2007-06-26 SG SG2011047032A patent/SG172735A1/en unknown
- 2007-06-26 JP JP2009518522A patent/JP2009541493A/ja active Pending
- 2007-06-26 CN CNA2007800241434A patent/CN101484159A/zh active Pending
- 2007-06-26 US US11/768,889 patent/US20080039496A1/en not_active Abandoned
-
2008
- 2008-12-11 IL IL195903A patent/IL195903A0/en unknown
-
2013
- 2013-08-15 JP JP2013168863A patent/JP2013227357A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109152933B (zh) | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 | |
| KR102287288B1 (ko) | 신규한 방법 | |
| JP2008545793A5 (enExample) | ||
| EP2627328B1 (en) | Combinations of serotonin receptor agonists for treatment of movement disorders | |
| JP7778745B2 (ja) | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| CN110267945A (zh) | 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途 | |
| CN107787323A (zh) | 用于抑制shp2活性的化合物和组合物 | |
| JP2013536833A5 (enExample) | ||
| JP2017517548A5 (enExample) | ||
| TW202317532A (zh) | Aak1抑制劑及其用途 | |
| JP2001521492A (ja) | １−フェニル−４−ベンジルピペラジン：ドーパミン受容体サブタイプ特異性リガンド（ｄ４） | |
| TWI462908B (zh) | 用於治療增生性失調症的化合物 | |
| JP2010500376A5 (enExample) | ||
| JP2022537358A5 (enExample) | ||
| WO2020143762A1 (en) | Ketamine pamoate and use thereof | |
| JP2024160326A (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| KR20080093453A (ko) | 4-아실아미노피리딘 유도체 매개된 신경조직발생 | |
| KR20230004662A (ko) | 1,5-디하이드로-2,4-벤조디아제핀-3-온 유도체 및 이의 응용 | |
| EP2032135A2 (en) | Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist | |
| JP2011517455A (ja) | Ｃ（１０）エチルエステルおよびｃ（１０）シクロプロピルエステル置換タキサン | |
| JP2008536844A5 (enExample) | ||
| AU2006275824B2 (en) | Method of improving wakefulness | |
| WO2025157284A1 (zh) | 包含prmt5抑制剂和化疗剂的药物组合物 | |
| PT1745786E (pt) | Compostos neuroprotetores e composições farmacêuticas que os compreendem | |
| DE60210329T2 (de) | Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren |